These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 29517084

  • 1. Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.
    Choudhry A, O'Brien SM.
    Drugs Today (Barc); 2017 Dec; 53(12):653-665. PubMed ID: 29517084
    [Abstract] [Full Text] [Related]

  • 2. Inotuzumab Ozogamicin: First Global Approval.
    Lamb YN.
    Drugs; 2017 Sep; 77(14):1603-1610. PubMed ID: 28819740
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
    Dahl J, Marx K, Jabbour E.
    Expert Rev Hematol; 2016 Sep; 9(4):329-34. PubMed ID: 26783163
    [Abstract] [Full Text] [Related]

  • 6. Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
    Yurkiewicz IR, Muffly L, Liedtke M.
    Drug Des Devel Ther; 2018 Sep; 12():2293-2300. PubMed ID: 30087554
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.
    Thota S, Advani A.
    Eur J Haematol; 2017 May; 98(5):425-434. PubMed ID: 28152223
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.
    Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M, York S, Ravandi F, Garris R, Kwari M, Faderl S, Cortes J, Champlin R, O'Brien S.
    Cancer; 2013 Aug 01; 119(15):2728-36. PubMed ID: 23633004
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
    Kantarjian HM, Stock W, Cassaday RD, DeAngelo DJ, Jabbour E, O'Brien SM, Stelljes M, Wang T, Paccagnella ML, Nguyen K, Sleight B, Vandendries E, Neuhof A, Laird AD, Advani AS.
    Clin Cancer Res; 2021 May 15; 27(10):2742-2754. PubMed ID: 33602684
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.